
Sensorion Reports Positive Early Data from First Audiogene Trial Cohort
Sensorion Reports Promising Early Data from Phase 1/2 Audiogene Gene Therapy Trial Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company focused on developing innovative therapies for hearing loss, has announced encouraging preliminary results from the first cohort of its Phase…












